Letter by Qin et al Regarding Article “Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure”

Puntos clave

• This letter aims to address findings regarding dapagliflozin's efficacy in patients with heart failure.
• Analysis of primary results from the DAPA ACT HF-TIMI 68 trial.
• Discussion of meta-analysis outcomes of sodium-glucose cotransporter-2 inhibitors.
• Focus on results in hospitalized heart failure patients.
• Dapagliflozin showed significant benefits for heart failure management.
• Meta-analysis indicated positive outcomes for sodium-glucose cotransporter-2 inhibitors.
• Clinical outcomes emphasized the importance of these findings for treatment strategies.